| Active substance |
Saxagliptin |
| Also known as |
BMS-477118 |
| Blood pressure |
Neutral effect on blood pressure |
| Chemical name |
(1S,3S,5S)-2-[(2S)-2-Amino-2-(3-hydroxytricyclo[3.3.1.1~3,7~]dec-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile |
| Dosage (medical) |
Typically 2.5 mg or 5 mg once daily |
| Dosage (sports) |
Not applicable |
| Effects |
Increases insulin release and decreases glucagon levels in the blood in a glucose-dependent manner |
| Formula |
C18H25N3O2 |
| Half-life |
Approximately 2.5 hours |
| Hepatotoxicity |
Low risk of hepatotoxicity |
| Lab Test |
Monitoring of hemoglobin A1c levels may be conducted to assess effectiveness |
| Main action |
Lower blood glucose levels by inhibiting the enzyme DPP-4 |
| Side effects |
Upper respiratory tract infection, urinary tract infection, headache, and hypersensitivity reactions such as skin rash and urticaria |
| Storage conditions |
Store at room temperature, away from moisture and heat |
| Strength |
5mg |
| Substance class |
Dipeptidyl peptidase-4 (DPP-4) inhibitor |
| Trade name |
Onglyza |
| Use in sports |
Not typically used in sports |
| Water Retention |
No significant effect on water retention |
| Manufacturer |
AstraZeneca Pharma Ltd. |
| Packing |
14 tabs/blister |
